These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29767751)

  • 1. Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients.
    Natsume S; Yamaguchi T; Takao M; Iijima T; Wakaume R; Takahashi K; Matsumoto H; Nakano D; Horiguchi SI; Koizumi K; Miyaki M
    Jpn J Clin Oncol; 2018 Jul; 48(7):609-618. PubMed ID: 29767751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases.
    Song Y; Wang L; Ran W; Li G; Xiao Y; Wang X; Zhang L; Xing X
    Front Genet; 2020; 11():96. PubMed ID: 32161617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in oncological outcomes and inflammatory biomarkers between right-sided and left-sided stage I-III colorectal adenocarcinoma.
    Guo D; Li X; Xie A; Cao Q; Zhang J; Zhang F; Li W; Chen J
    J Clin Lab Anal; 2020 Apr; 34(4):e23132. PubMed ID: 31755593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
    Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
    Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and molecular differences in colorectal cancer according to location.
    Hsu YL; Lin CC; Jiang JK; Lin HH; Lan YT; Wang HS; Yang SH; Chen WS; Lin TC; Lin JK; Lin PC; Chang SC
    Int J Biol Markers; 2019 Mar; 34(1):47-53. PubMed ID: 30854932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
    Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
    Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of clinicopathological features and prognosis of sporadic synchronous multiple primary colorectal cancers].
    Qin ZF; Xu GH; Zhou SQ; Zheng PW; Zhu YP; Ju HX; Li DC; Ma DN
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1171-1178. PubMed ID: 38110279
    [No Abstract]   [Full Text] [Related]  

  • 9. RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer.
    Matsumoto A; Shimada Y; Nakano M; Oyanagi H; Tajima Y; Nakano M; Kameyama H; Hirose Y; Ichikawa H; Nagahashi M; Nogami H; Maruyama S; Takii Y; Ling Y; Okuda S; Wakai T
    Oncol Rep; 2020 Jun; 43(6):1853-1862. PubMed ID: 32236609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left-Sided microsatellite unstable colorectal cancers show less frequent methylation of hMLH1 and CpG island methylator phenotype than right-sided ones.
    Tanaka J; Watanabe T; Kanazawa T; Tada T; Kazama Y; Tanaka T; Nagawa H
    J Surg Oncol; 2007 Dec; 96(7):611-8. PubMed ID: 17786961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
    Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A
    Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
    Chen KH; Shao YY; Chen HM; Lin YL; Lin ZZ; Lai MS; Cheng AL; Yeh KH
    BMC Cancer; 2016 May; 16():327. PubMed ID: 27221731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer.
    Liu J; Tang L; Yi J; Li G; Lu Y; Xu Y; Zhao S; Mao R; Li X; Ren L; Wang K
    BMC Gastroenterol; 2019 Nov; 19(1):173. PubMed ID: 31690257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
    Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
    J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status.
    Bae JM; Kim MJ; Kim JH; Koh JM; Cho NY; Kim TY; Kang GH
    Virchows Arch; 2011 Jul; 459(1):55-63. PubMed ID: 21494758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
    Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
    Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
    Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
    World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.
    Bae JM; Kim JH; Cho NY; Kim TY; Kang GH
    Br J Cancer; 2013 Aug; 109(4):1004-12. PubMed ID: 23900220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.